Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of pamrevlumab (FG-3019) in idiopathic pulmonary fibrosis
2014-005658-20Phase 2Completed
- Sponsor
- FibroGen
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Pamrevlumab with Placebo (2 arms). Primary endpoint: Safety and tolerability of pamrevlumab (FG-3019). Started Dec 2015; status: completed.
02
Drugs
pamrevlumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2014-005658-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005658-20.